Results 111 to 120 of about 41,522 (262)

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

The discovery and development of ensifentrine: A novel inhaled dual PDE3/4 inhibitor having ‘bifunctional’ bronchodilator and anti‐inflammatory activity

British Journal of Pharmacology, EarlyView.
Abstract Ensifentrine (formerly called RPL 554) is a novel, first in class, inhaled bifunctional dual PDE3/4 inhibitor for the treatment of chronic respiratory diseases. Ensifentrine exhibits both bronchodilation via PDE3 inhibition and anti‐inflammatory activity via PDE4 inhibition.
Clive Page
wiley   +1 more source

A Real‐World Controlled Multicentre Study Evaluating the Association Between Benralizumab Therapy and Major Outcomes in Severe Asthma

Clinical &Experimental Allergy, EarlyView.
Among patients with severe eosinophilic asthma, benralizumab was associated with greater improvements in asthma outcomes—such as improved asthma control, quality of life and remission rates—compared to biologic‐naïve patients. ABSTRACT Background Real‐world data on benralizumab in patients with severe eosinophilic asthma–while controlling for ...
Dennis Thomas, Vanessa M. McDonald, Gijo Thomas, Joy Lee, Li Ping Chung, Matthew Peters, Shakti D. Shukla, Yuto Hamada, Erin S. Harvey, Michael Fricker, Hayley See, Rejoy Sabin Thomas, Claude S. Farah, Andrew Gillman, Constance H. Katelaris, Gregory P. Katsoulotos, David Langton, Peter G. Middleton, Paul Reynolds, Janet Rimmer, Francis Thien, Stephen Vincent, John W. Upham, Peter G. Gibson   +23 more
wiley   +1 more source

Inhaled Corticosteroids and Non-Tuberculous Mycobacteria Risk in Patients with COPD. [PDF]

J Clin Med
Borremose EM, Dahl VN, Vognsen AK, Lillebaek T, Fløe A, Biering-Sørensen T, Bonnesen B, Eklöf J, Sivapalan P, Jensen JS.   +9 more
europepmc   +1 more source

Emerging Paediatric Uses of Dupilumab Beyond Approvals

Clinical &Experimental Allergy, EarlyView.
Dupilumab, through IL‐4Rα blockade, shows promising efficacy beyond approved indications in paediatric diseases driven by T2 inflammation. Emerging evidence—mainly from small studies—supports improvements in disease severity and quality of life, highlighting its potential as a targeted, steroid‐sparing therapy while underscoring the need for ...
Simone Foti Randazzese, Anna Calamita, Diletta D'Angelo, Alessia Marseglia, Esther Mesa Lombardero, Sara Pedersoli, Micol Tedeschi, Mara De Amici, Sara Manti, Valeria Brazzelli, Amelia Licari, Gian Luigi Marseglia   +11 more
wiley   +1 more source

As-needed inhaled corticosteroids in asthma: from evidence to implementation. [PDF]

Curr Opin Pulm Med
Merrell E, Khurana S.
europepmc   +1 more source

Inhaled Corticosteroids and the Risk of Lung Cancer in Patients with Bronchiectasis. [PDF]

J Clin Med
Lee C, Lee GY, Shin J, Lee JY, Lee JH.
europepmc   +1 more source

Processionary Moth Exposure in Europe: Toxic–Irritant and Immunoglobulin E‐Mediated Endotypes, Diagnosis and Management

Clinical &Experimental Allergy, EarlyView.
Most reactions are toxic–irritant, driven by epithelial injury and neuro‐inflammatory activation. IgE‐mediated allergy is less common but may cause immediate systemic reactions. Endotype differentiation guides diagnosis, risk stratification and management.
Prasad Dasari, Josefine Haas, Wolfgang Rohe, Kai Gloyna, Christoph Viebahn, Susann Forkel, Michael Szardenings, Christine Stadelmann, Michael P. Schön, Timo Buhl   +9 more
wiley   +1 more source

Association between inhaled corticosteroids and risk of cardiovascular mortality in patients with COPD: a systematic review and meta-analysis. [PDF]

Eur Respir Rev
Yang MJ, Zhang Y, Dai HY, He W, Ying XM, Jin XX, Guo SL, Sin DD.   +7 more
europepmc   +1 more source

Patch Testing in Paediatric Drug Hypersensitivity Reactions: Current Evidence and Clinical Implications

Contact Dermatitis, EarlyView.
ABSTRACT Drug hypersensitivity reactions (DHRs) are common in children and are diagnostically challenging, with cutaneous manifestations being the most common presentation. Patch testing (PT) is a well‐established tool for investigating delayed T‐cell‐mediated reactions and is widely used in patients with contact dermatitis.
Gabriele Simonetti, Francesco Catamerò, Giulia Liccioli, Leonardo Tomei, Simona Barni, Mattia Giovannini, Lucrezia Sarti, Francesca Mori   +7 more
wiley   +1 more source